银屑病关节炎临床试验中的安慰剂反应:系统评价与meta分析
该系统评价与meta分析纳入42项银屑病关节炎随机对照试验(共5050例安慰剂组患者),发现安慰剂组ACR20应答率为20.3%(95%CI:18.6%,22.1%),且随发表年份每增加5年,安慰剂应答的 odds 增加15%(95%CI:2.9%,29.8%)。但安慰剂反应与积极治疗效应量无关,尽管积极治疗风险差随发表年份每5年下降(β=-0.053,95%CI:-0.099,-0.007)。
要点
- 银屑病关节炎RCT中安慰剂组ACR20应答率合并为20.3%(95%CI:18.6%,22.1%)。
- 发表年份每增加5年,安慰剂应答 odds 增加15%(95%CI:2.9%,29.8%)。
- 安慰剂反应与积极治疗效应量无关联。
核心结论
- 银屑病关节炎RCT中ACR20安慰剂应答率随时间增加,但与积极治疗效应量无关。
研究设计与样本
- 系统评价与随机效应meta分析,检索多个数据库至2020年12月20日,纳入42项安慰剂对照RCT(5050例安慰剂组患者)。
主要发现
- 安慰剂组ACR20合并应答率为20.3%(95%CI:18.6%,22.1%;预测区间11.7-29.0%),试验间异质性显著(I2=56.8%,P<0.005)。
- 积极治疗与安慰剂的合并风险差为27%(95%CI:24%,31%)。
- 多变量meta回归显示,发表年份每增加5年,安慰剂应答的 odds 增加15%(95%CI:2.9%,29.8%;P=0.016)。
- 发表年份每增加5年,积极治疗风险差下降(β=-0.053,95%CI:-0.099,-0.007;P=0.024),但与安慰剂反应无关。
关键数值与推荐
- 安慰剂组ACR20应答率20.3%(95%CI:18.6%,22.1%)。
- 积极治疗 vs 安慰剂风险差27%(95%CI:24%,31%)。
- 发表年份每5年安慰剂应答 odds 增加15%(95%CI:2.9%,29.8%)。
- 发表年份每5年积极治疗风险差 β=-0.053(95%CI:-0.099,-0.007)。
临床怎么用
- 解读银屑病关节炎RCT时需考虑随时间升高的安慰剂应答率,但安慰剂反应不削弱积极治疗效应量的判断。
局限性
- 试验间异质性显著(I2=56.8%),28项试验偏倚风险低、4项高、10项有些担忧。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine the placebo response rate in PsA randomized clinical trials (RCTs), its contributing factors and impact on the effect size of active treatments. METHODS: We searched multiple databases, from inception to 20 December 2020, for placebo-controlled RCTs in PsA. We used a random-effects meta-analysis to pool the response rates for the ACR20 criteria in the placebo arm, determined the risk difference for treatment vs placebo, and used meta-regression to determine the factors associated with placebo response rates. The risk of bias was assessed in duplicate. The study protocol was registered with PROSPERO: CRD42021226000. RESULTS: We included 42 RCTs (5050 patients receiving placebo) published between 2000 and 2020. The risk of bias was low in 28 trials, high in four, and with some concerns in 10. The pooled placebo response rate was 20.3% (95% CI: 18.6%, 22.1%; predicted intervals, 11.7-29.0%), with significant between-trial heterogeneity (I2 = 56.8%, P < 0.005). The pooled risk difference for treatment vs placebo was 27% (95% CI: 24%, 31%). In the multivariable meta-regression, there was a 15% (95% CI: 2.9%, 29.8%) increase in the odds of achieving the placebo response for each 5-year increment in publication year (P = 0.016). In addition, the active treatment risk difference decreased for every 5-year increment in publication year (β = -0.053, 95% CI: -0.099, -0.007; P = 0.024) but was not associated with the placebo response. CONCLUSION: Despite increasing over time, the placebo response for ACR20 in PsA RCTs was not associated with the active treatment effect size.
引用
- Erre GL, Mavridis D, Woodman RJ, et al. Placebo response in psoriatic arthritis clinical trials: a systematic review and meta-analysis. Rheumatology (Oxford). 2022. PMID: 34664615. doi:10.1093/rheumatology/keab774
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。